Tình trạng pháp lý: Hợp chất đang phát triển; hạn chế bằng sáng chế, chỉ dùng cho R&D/nộp hồ sơ pháp lý
Tên IUPAC: N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
Số EC: 806-670-8
Khối lượng phân tử: 506.6
Công thức hoá học: C₂₇H₃₂F₂N₈
Số CAS: 1231929-97-7
Ứng dụng: Chất ức chế CDK4/6 cho ung thư vú thụ thể hormone dương tính
Status: Pipeline
Development phase: Under development
Therapeutic cat.: Oncology
Polymorphic form: Form III
OEB No.: 4
Samples: Q1 2025

Thông tin khác

Mô tả thêm:

Abemaciclib (CAS 1231929-97-7, polymorphic Form III) is a pipeline oncology API under development by Polpharma, with samples expected in Q1 2025 at containment level OEB 4. It is a kinase inhibitor used, in combination with aromatase inhibitors or fulvestrant, to treat hormone receptor-positive breast cancer, including advanced and early-stage disease. Polpharma notes the product is intended only for regulatory submission or R&D purposes and is not offered in markets where it remains under patent protection; it is otherwise available across North America, Central/South America, Western and Eastern Europe, Australasia, and Asia.